RecruitingPhase 2NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Studying Carcinoma of esophagus, salivary gland type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jazz Pharmaceuticals
- Intervention
- Zanidatamab(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (21)
- Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
- Rocky Mountain Cancer Center, Littleton, Colorado, United States
- Florida Cancer Specialists - South, Fort Myers, Florida, United States
- Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
- Florida Cancer Specialists - North, St. Petersburg, Florida, United States
- Florida Cancer Specialists - East, West Palm Beach, Florida, United States
- Affiliated Oncologists, Chicago Ridge, Illinois, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Alliance Cancer Specialists, Horsham, Pennsylvania, United States
- Tennessee Cancer Specialists, Knoxville, Tennessee, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Texas Oncology - West Texas, Amarillo, Texas, United States
- Texas Oncology - DFW, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Texas Oncology - San Antonio, San Antonio, Texas, United States
- +6 more locations on ClinicalTrials.gov
Collaborators
Jazz Pharmaceuticals Ireland Limited
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06695845 on ClinicalTrials.govOther trials for Carcinoma of esophagus, salivary gland type
Additional recruiting or active studies for the same condition.
See all trials for Carcinoma of esophagus, salivary gland type →